{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:01:19Z","timestamp":1784599279469,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005934","name":"Malm\u00f6 University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005934","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer is one of the most common cancers among women, with improved therapies reducing mortality. Antiresorptive (AR) therapy is crucial for managing bone loss and skeletal complications in patients with cancer. However, high-dose AR therapy may carry a significant risk of medication-related osteonecrosis of the jaw (MRONJ). This study aimed to investigate the incidence of MRONJ and its risk factors in patients with diagnosed breast cancer undergoing either biannual postoperative bisphosphonate therapy or high-dose AR therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study followed 220 female patients receiving AR therapy in Sweden, from 2015 to 2020. Oral health status was assessed before and during AR therapy, collecting data on MRONJ incidence, dental procedures, and data on breast cancer characteristics. Statistical analyses included Fisher\u2019s exact tests, and group differences in Kaplan-Meier curves were assessed using the log-rank test.\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 was considered statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort comprised 119 patients on biannual AR therapy and 101 patients on high-dose AR therapy. Nine patients (4.0%) developed bone metastases and transitioned to high-dose AR therapy after a mean interval of 237 days; of these, 55.5% subsequently switched from bisphosphonates to denosumab. MRONJ cumulative incidence was 5.5% in the overall cohort and 11.9% in the high-dose group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001); no MRONJ cases occurred in the biannual group. Tooth extractions (30.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), localisation to the mandible (83.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.039) and number of AR doses (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) were significantly associated with the development of MRONJ. Notably, spontaneous MRONJ accounted for 41.7% of cases. Baseline DMFT did not differ, but MRONJ patients had a higher DMFT increment during follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study identifies a significant association between high-dose AR therapy and the development of MRONJ in breast cancer patients, with tooth extractions, mandibular localisation, and cumulative AR exposure identified as risk factors. MRONJ was not observed in the biannual AR therapy group. These findings underscore the importance of comprehensive dental assessments and early risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12903-026-09289-0","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:43:18Z","timestamp":1784076198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medication-related osteonecrosis of the jaw in breast cancer patients: a longitudinal observational Swedish study of oral health and antiresorptive use"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-598X","authenticated-orcid":false,"given":"Magdalena","family":"Korytowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Lengstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1334-7616","authenticated-orcid":false,"given":"Anna","family":"Ljunggren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Erik","family":"Isberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-1090","authenticated-orcid":false,"given":"Cecilia","family":"Larsson Wexell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"9289_CR1","unstructured":"Anna Ehinger AK, Eugenia Colon-Cervantes \u00c5sa, Rundgren J, van Brakel A, Boden A, Bauer, Gunilla Rask. Breast cancer: National Care Program for Breast Cancer in Sweden. 2024 22 Oktober 2024]; 5.1:[Available from: https:\/\/kunskapsbanken.cancercentrum.se\/globalassets\/cancerdiagnoser\/brost\/vardprogram\/nationellt-vardprogram-brostcancer.pdf."},{"issue":"5","key":"9289_CR2","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, et al. American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022;80(5):920\u201343.","journal-title":"J Oral Maxillofac Surg"},{"issue":"9","key":"9289_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115\u20137.","journal-title":"J Oral Maxillofac Surg"},{"issue":"22","key":"9289_CR4","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","volume":"21","author":"CA Migliorati","year":"2003","unstructured":"Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21(22):4253\u20134.","journal-title":"J Clin Oncol"},{"issue":"6","key":"9289_CR5","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ijom.2021.11.007","volume":"51","author":"M El-Rabbany","year":"2022","unstructured":"El-Rabbany M, et al. Development and evaluation of the clinimetric properties of the Medication-Related Osteonecrosis of the Jaw Quality of Life Questionnaire (MRONJ-QoL). Int J Oral Maxillofac Surg. 2022;51(6):768\u201375.","journal-title":"Int J Oral Maxillofac Surg"},{"key":"9289_CR6","doi-asserted-by":"crossref","unstructured":"Di Fede O, Yarom N, Bagan J, Otto S, Fedele S. Adverse Reactions to Anticancer Drugs in the Oral Cavity. Biomed Res Int. 2018;2018:1372874.","DOI":"10.1155\/2018\/1372874"},{"key":"9289_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/EDBK_200981","volume":"38","author":"EA Mittendorf","year":"2018","unstructured":"Mittendorf EA, et al. Incorporating Biology Into Breast Cancer Staging: American Joint Committee on Cancer, Eighth Edition, Revisions and Beyond. Am Soc Clin Oncol Educ Book. 2018;38:38\u201346.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"9289_CR8","doi-asserted-by":"publisher","unstructured":"Young J, Asaoka M, Ghasemi F, Chida K, Roy AM, Yan L, Hakamada K, Takabe K. The American Joint Committee on Cancer (AJCC) Breast Cancer Staging, Eighth Edition, is more Reflective of Cancer Biology than the Seventh Edition. Ann Surg Oncol. 2025;32(5):3268\u20133277. https:\/\/doi.org\/10.1245\/s10434-025-16889-7.","DOI":"10.1245\/s10434-025-16889-7"},{"issue":"5","key":"9289_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11864-021-00835-2","volume":"22","author":"A Diana","year":"2021","unstructured":"Diana A, et al. Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy. Curr Treat Options Oncol. 2021;22(5):45.","journal-title":"Curr Treat Options Oncol"},{"key":"9289_CR10","doi-asserted-by":"publisher","first-page":"100355","DOI":"10.1016\/j.jbo.2021.100355","volume":"28","author":"K Waqas","year":"2021","unstructured":"Waqas K, et al. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol. 2021;28:100355.","journal-title":"J Bone Oncol"},{"key":"9289_CR11","doi-asserted-by":"publisher","unstructured":"Chukir T, Liu Y, Farooki A. Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer. Br J Clin Pharmacol. 2019;85(6):1125\u20131135. https:\/\/doi.org\/10.1111\/bcp.13834.","DOI":"10.1111\/bcp.13834"},{"issue":"3","key":"9289_CR12","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1530\/JOE-19-0077","volume":"241","author":"SK Ramchand","year":"2019","unstructured":"Ramchand SK, et al. The effects of adjuvant endocrine therapy on bone health in women with breast cancer. J Endocrinol. 2019;241(3):R111\u201324.","journal-title":"J Endocrinol"},{"issue":"3","key":"9289_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/annonc\/mdv617","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol. 2016;27(3):379\u201390.","journal-title":"Ann Oncol"},{"issue":"2","key":"9289_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24(2):398\u2013405.","journal-title":"Ann Oncol"},{"key":"9289_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jbo.2018.09.008","volume":"13","author":"RE Coleman","year":"2018","unstructured":"Coleman RE, et al. Benefits and risks of adjuvant treatment with zoledronic acid in stage II\/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01\/04). J Bone Oncol. 2018;13:123\u201335.","journal-title":"J Bone Oncol"},{"issue":"5","key":"9289_CR16","first-page":"504","volume":"19","author":"AM Brufsky","year":"2013","unstructured":"Brufsky AM, et al. Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study. Breast J. 2013;19(5):504\u201311.","journal-title":"Breast J"},{"issue":"21","key":"9289_CR17","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1002\/cncr.33802","volume":"127","author":"V Ehrenstein","year":"2021","unstructured":"Ehrenstein V, et al. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden. Cancer. 2021;127(21):4050\u20138.","journal-title":"Cancer"},{"key":"9289_CR18","doi-asserted-by":"publisher","unstructured":"Brunner C, Arvandi M, Marth C, Egle D, Baumgart F, Emmelheinz M, Walch B, Lercher J, Iannetti C, W\u00f6ll E, Pechlaner A, Zabernigg A, Volgger B, Castellan M, Andraschofsky OT, Markl A, Hubalek M, Schnallinger M, Puntscher S, Siebert U, Sch\u00f6nherr S, Forer L, Bruckmoser E, Laimer J. Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study. J Clin Oncol. 2025;43(2):180\u2013188. https:\/\/doi.org\/10.1200\/JCO.24.00171","DOI":"10.1200\/JCO.24.00171"},{"issue":"2","key":"9289_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/sj.bdj.2017.1039","volume":"224","author":"V Patel","year":"2018","unstructured":"Patel V, et al. MRONJ risk of adjuvant bisphosphonates in early stage breast cancer. Br Dent J. 2018;224(2):74\u20139.","journal-title":"Br Dent J"},{"issue":"5","key":"9289_CR20","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1007\/s00520-020-05748-8","volume":"29","author":"DA Kizub","year":"2021","unstructured":"Kizub DA, et al. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). Support Care Cancer. 2021;29(5):2509\u201317.","journal-title":"Support Care Cancer"},{"issue":"1","key":"9289_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12903-023-02732-6","volume":"23","author":"R Mauceri","year":"2023","unstructured":"Mauceri R, et al. MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series. BMC Oral Health. 2023;23(1):71.","journal-title":"BMC Oral Health"},{"issue":"5","key":"9289_CR22","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341\u20137.","journal-title":"Ann Oncol"},{"key":"9289_CR23","doi-asserted-by":"publisher","unstructured":"Liu C, Xiong YT, Zhu T, Liu W, Tang W, Zeng W. Management of Tooth Extraction in Patients Taking Antiresorptive Drugs: An Evidence Mapping Review and Meta-Analysis. J Clin Med. 2022;12(1):239. https:\/\/doi.org\/10.3390\/jcm12010239.","DOI":"10.3390\/jcm12010239"},{"key":"9289_CR24","doi-asserted-by":"publisher","unstructured":"Avishai G, Muchnik D, Masri D, Zlotogorski-Hurvitz A, Chaushu L. Minimizing MRONJ after Tooth Extraction in Cancer Patients Receiving Bone-Modifying Agents. J Clin Med. 2022;11(7):1807. https:\/\/doi.org\/10.3390\/jcm11071807.","DOI":"10.3390\/jcm11071807"},{"key":"9289_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/CLEP.S71796","volume":"7","author":"M Schiodt","year":"2015","unstructured":"Schiodt M, et al. Existing data sources for clinical epidemiology: Scandinavian Cohort for osteonecrosis of the jaw - work in progress and challenges. Clin Epidemiol. 2015;7:107\u201316.","journal-title":"Clin Epidemiol"},{"issue":"12","key":"9289_CR26","doi-asserted-by":"publisher","first-page":"e10693","DOI":"10.1002\/jbm4.10693","volume":"6","author":"C Micheletti","year":"2022","unstructured":"Micheletti C, et al. Multimodal and Multiscale Characterization of the Bone-Bacteria Interface in a Case of Medication-Related Osteonecrosis of the Jaw. JBMR Plus. 2022;6(12):e10693.","journal-title":"JBMR Plus"},{"issue":"1","key":"9289_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/00016357.2021.1934535","volume":"80","author":"J Olsson","year":"2022","unstructured":"Olsson J, et al. Pre-medical dental evaluation and treatment of oral infection - a survey study among hospital-affiliated dentists in Sweden. Acta Odontol Scand. 2022;80(1):29\u201337.","journal-title":"Acta Odontol Scand"},{"issue":"2","key":"9289_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/00016357.2019.1655586","volume":"78","author":"M Dahlgren","year":"2020","unstructured":"Dahlgren M, Larsson C, Wexell. Uncertainty managing patients treated with antiresorptive drugs: a cross-sectional study of attitudes and self-reported behavior among dentists in Sweden. Acta Odontol Scand. 2020;78(2):109\u201317.","journal-title":"Acta Odontol Scand"},{"issue":"4","key":"9289_CR29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/oral2040026","volume":"2","author":"R Mauceri","year":"2022","unstructured":"Mauceri R, Coppini M, Campisi G. Onset of MRONJ in Breast Cancer Patients after Switching from Low to High Dose of Bone Modifying Agents Due to Bone Metastases Development: A Single Center Retrospective Cohort Study. Oral. 2022;2(4):274\u201385.","journal-title":"Oral"},{"key":"9289_CR30","unstructured":"Petersen PE, Baez, Ramon J, World, Organization H. Oral health surveys: basic methods. 5th ed ed. 2013: World Health Organization. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/b00e659f-ab38-4e61-b786-0152d91b5f1b\/content"},{"issue":"10","key":"9289_CR31","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update. J Oral Maxillofac Surg. 2014;72(10):1938\u201356.","journal-title":"J Oral Maxillofac Surg"},{"issue":"9814","key":"9289_CR32","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Peto R, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432\u201344.","journal-title":"Lancet"},{"issue":"2","key":"9289_CR33","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00520-020-05556-0","volume":"29","author":"TL Ng","year":"2021","unstructured":"Ng TL, et al. Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. Support Care Cancer. 2021;29(2):925\u201343.","journal-title":"Support Care Cancer"},{"issue":"2","key":"9289_CR34","first-page":"69","volume":"39","author":"O Norderyd","year":"2015","unstructured":"Norderyd O, et al. Oral health of individuals aged 3\u201380 years in J\u00f6nk\u00f6ping, Sweden during 40 years (1973\u20132013). II. Review of clinical and radiographic findings. Swed Dent J. 2015;39(2):69\u201386.","journal-title":"Swed Dent J"},{"issue":"4","key":"9289_CR35","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.4317\/medoral.24318","volume":"26","author":"V Fusco","year":"2021","unstructured":"Fusco V, et al. A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy. Med Oral Patol Oral Cir Bucal. 2021;26(4):e466\u201373.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"9289_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","volume":"69","author":"S Otto","year":"2018","unstructured":"Otto S, et al. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177\u201387.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"9289_CR37","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.oraloncology.2011.02.024","volume":"47","author":"A Bedogni","year":"2011","unstructured":"Bedogni A, et al. Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis. Oral Oncol. 2011;47(5):420\u20134.","journal-title":"Oral Oncol"},{"issue":"3","key":"9289_CR38","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","volume":"20","author":"M Gnant","year":"2019","unstructured":"Gnant M, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):339\u201351.","journal-title":"Lancet Oncol"},{"issue":"2","key":"9289_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/17843286.2017.1348001","volume":"73","author":"T Loyson","year":"2018","unstructured":"Loyson T, et al. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belg. 2018;73(2):100\u20139.","journal-title":"Acta Clin Belg"},{"issue":"1","key":"9289_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.oooo.2017.09.014","volume":"125","author":"N Yarom","year":"2018","unstructured":"Yarom N, et al. Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(1):27\u201330.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"6","key":"9289_CR41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.oooo.2018.02.010","volume":"125","author":"T Higuchi","year":"2018","unstructured":"Higuchi T, et al. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(6):547\u201351.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12903-026-09289-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-026-09289-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-026-09289-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:02:31Z","timestamp":1784595751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12903-026-09289-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9289"],"URL":"https:\/\/doi.org\/10.1186\/s12903-026-09289-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7052160\/v1","asserted-by":"object"}]},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for this study was granted by the Swedish Ethical Review Authority, Uppsala (reference number: 2020-00346). The study was retrospective and non-interventional, based on analysis of existing medical records without direct patient contact. According to Swedish law (Lag [2003:460], Section 21) and the Declaration of Helsinki (WMA, 2023), informed consent was not required as the research could not feasibly be conducted otherwise, addressed an important public interest, and appropriate measures were in place to protect participants\u2019 privacy.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1317"}}